Prohibitin ligands: a growing armamentarium to tackle cancers, osteoporosis, inflammatory, cardiac and neurological diseases
- 15 February 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cellular and Molecular Life Sciences
- Vol. 77 (18), 3525-3546
- https://doi.org/10.1007/s00018-020-03475-1
Abstract
Over the last three decades, the scaffold proteins prohibitins-1 and -2 (PHB1/2) have emerged as key signaling proteins regulating a myriad of signaling pathways in health and diseases. Small molecules targeting PHBs display promising effects against cancers, osteoporosis, inflammatory, cardiac and neurodegenerative diseases. This review provides an updated overview of the various classes of PHB ligands, with an emphasis on their mechanism of action and therapeutic potential. We also describe how these ligands have been used to explore PHB signaling in different physiological and pathological settings.Keywords
Funding Information
- National Natural Science Foundation of China (81673296)
- the start-up Foundation from Tianjin University of Science & Technology
- Deutsche Forschungsgemeinschaft
- Collaborative Research Center 1292
This publication has 113 references indexed in Scilit:
- A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese MonkeysScience Translational Medicine, 2011
- Flavaglines Alleviate Doxorubicin Cardiotoxicity: Implication of Hsp27PLOS ONE, 2011
- A novel role for mitochondrial sphingosine-1-phosphate produced by sphingosine kinase-2 in PTP-mediated cell survival during cardioprotectionBasic Research in Cardiology, 2011
- Skp2B Overexpression Alters a Prohibitin-p53 Axis and the Transcription of PAPP-A, the Protease of Insulin-Like Growth Factor Binding Protein 4PLOS ONE, 2011
- The role and therapeutic potential of prohibitin in diseaseBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- Skp2 and Skp2B team up against Rb and p53.Cell Division, 2011
- Akt–RSK–S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine KinasesScience Signaling, 2010
- Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cellsProceedings of the National Academy of Sciences of the United States of America, 2010
- Interaction between O-GlcNAc Modification and Tyrosine Phosphorylation of Prohibitin: Implication for a Novel Binary SwitchPLOS ONE, 2009
- Differential regulation of human YY1 and caspase 7 promoters by prohibitin through E2F1 and p53 binding sitesBiochemical Journal, 2006